Artelo Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
$14.0 Million in Cash and Investments as of June 30, 2023; Cash Runway Expected to Support Operations into the Second...
$14.0 Million in Cash and Investments as of June 30, 2023; Cash Runway Expected to Support Operations into the Second...
ATLANTA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- The Georgia Health Information Network (GaHIN), Georgia’s state-designated health information exchange (HIE), has...
Presented positive 36-week results from the Phase 2b ORIGIN clinical trial of atacicept in IgAN as a late breaking clinical...
Figure 1 Patient Case Study Example A Figure 2 Patient Case Study Example B Figure 3 Clearing in a lawn...
Tigris Trial Enrollment Reaches 71 PatientsTORONTO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:...
OXFORD, United Kingdom, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the...
Strong Sales of $5.5 million alongside Drug Partnering AgreementMISSISSAUGA, Ontario, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX:...
NEW YORK, NY, Aug. 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Applied UV, Inc. (NASDAQ: AUVI), a pioneer in...
Topline results of the STRIDE study, the pivotal mavodelpar clinical trial in adult patients with primary mitochondrial myopathies (PMM) due...
- Randomized Phase 2 Trial in 2L Metastatic Gastric Cancer Planned to Launch at Memorial Sloan Kettering Cancer Center - iNKT...
First Tranche of CAD $1,000,000 Secured From Chairman JJ Wilson’s Catcher Investments Ltd. JJ Wilson Director and non-executive Chair of...
Alimera Acquired U.S. Commercial Rights to YUTIQ®Landmark NEW DAY Study Completed Enrollment with over 300 PatientsConsolidated Net Revenue of $17.5...
DOYLESTOWN, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical...
• Quarter highlighted by the Emergency Use Authorization (EUA) and commercial launch of Gohibic (vilobelimab) in the United States • Oral C5aR inhibitor...
On track to present initial data from Phase 1/2 clinical trial of MRT-2359 for MYC-driven solid tumors in the second...
- Phase 1/1b clinical trial for IL-2 INDUKINE™ WTX-124 progressing in patients with advanced or metastatic solid tumors; initial first-in-human...
- Continued Progress in Expanding and Advancing Clinical Pipeline -- Conference Call Today at 8:30 a.m. ET - ATLANTA, Aug....
HOOKIPA reported positive preliminary Phase 2 data on HB-200 in combination with pembrolizumab in 1st-line setting for advanced head and...
NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine (Flu/Ara-C) lymphodepletion regimenNKX019 clinical data presented at...
Regulatory progress for govorestat (AT-007) for the treatment of Classic Galactosemia, with potential NDA submission based on discussions with the...